Why the study?
Does long-term propafenone therapy cause dose-limiting toxic side effects in patients with cardiac arrhythmia?
Does long-term propafenone therapy cause dose-limiting toxic side effects in patients with cardiac arrhythmia?
Long-term propafenone therapy frequently causes mild, dose-related side effects, but infrequently requires drug discontinuation.
Answers are grounded in this paper and cite their sources.
Propafenone side effects common yet rarely limiting in this cohort; leaves open need for randomized comparisons in arrhythmia management.
Long term propafenone therapy was initiated in 774 patients who were evaluated at 27 centers in the United States. The average duration of therapy was 183 days. During the treatment period, at least one toxic side effect occurred in 448 patients (58%). The most common reported adverse reactions were cardiovascular in 209 patients (27%), central nervous system in 160 patients (21%), and gastrointestinal in 159 patients (21%). Of those with cardiovascular side effects, 41 (5.3%) had aggravation of arrhythmia, 26 (3.4%) had the induction or worsening of congestive heart failure, and 65 (8.4%) had new conduction abnormalities. Although side effects were frequent, drug discontinuation due to the adverse reaction was necessary in only 114 patients (14.7%). The majority of side effects were dose related especially when 900 mg/day was administered. Additionally, the incidence of toxicity was directly related to age. We conclude that side effects are frequent during long‐term propafenone therapy, but most are mild, dose related, and do not limit the use of the drug. Drug discontinuation because of an adverse reaction is only infrequently required. It is recommended that drug therapy begin with low doses (150 mg t.i.d) with careful and slow titration up to a maximum of 900 mg/day.
No takes yet. Share an insight, caveat, or question.
Ravid et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: